Everolimus is the first mTOR inhibitor approved as a treatment option in the USA and in Europe for patients with subependymal giant-cell astrocytomas (SEGAs) associated with TSC. The gene discussed is MTOR; the disease is astrocytoma (excluding glioblastoma).